Gyre Therapeutics Inc (GYRE) USD0.001
$1.23
(10.34%)
- Add to watchlist
- This stock can be held in a
$1.23
(10.34%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$1.23
(10.34%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Contact details
Important dates
General stock information
- Short code:
- GYRE
- ISIN:
- US4037831033
- Market cap:
- $1.11 billion
- Shares in issue:
- 93.52 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.